These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 35413392

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK, Singh R.
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
    Cao Y, Li P, Li Y, Han Y.
    ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
    [Abstract] [Full Text] [Related]

  • 5. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.
    Circulation; 2019 May 28; 139(22):2528-2536. PubMed ID: 30882238
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H.
    Cardiovasc Diabetol; 2021 Apr 22; 20(1):83. PubMed ID: 33888126
    [Abstract] [Full Text] [Related]

  • 8. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ, Zhang ZY, Yan Q, Cao HL, Zhao YJ, Yang B, Li J.
    ESC Heart Fail; 2023 Apr 22; 10(2):1314-1325. PubMed ID: 36722326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis.
    Pozzi A, Cirelli C, Merlo A, Rea F, Scangiuzzi C, Tavano E, Iorio A, Kristensen SL, Wong C, Iacovoni A, Corrado G.
    Heart Fail Rev; 2024 Jan 22; 29(1):207-217. PubMed ID: 37917192
    [Abstract] [Full Text] [Related]

  • 12. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S, Kulthamrongsri N, Owattanapanich W, Krittayaphong R.
    Front Cardiovasc Med; 2023 Jan 22; 10():1046194. PubMed ID: 36824458
    [Abstract] [Full Text] [Related]

  • 13. SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.
    Razuk V, Chiarito M, Cao D, Nicolas J, Pivato CA, Camaj A, Power D, Beerkens F, Jones D, Alter A, Mathew A, Spirito A, Contreras JP, Dangas GD, Mehran R.
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep 03; 8(6):557-567. PubMed ID: 35021205
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Sep 03; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 16. Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure.
    Shrestha DB, Budhathoki P, Sedhai YR, Karki P, Gurung S, Raut S, Damonte JI, Del Buono MG, Mojadidi MK, Elgendy IY, Patel T, Patel NK.
    J Cardiovasc Pharmacol; 2021 Oct 01; 78(4):501-514. PubMed ID: 34269700
    [Abstract] [Full Text] [Related]

  • 17. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y, Gao T, Meng C, Li S, Bi L, Geng Y, Zhang P.
    Eur J Med Res; 2022 Dec 29; 27(1):314. PubMed ID: 36581880
    [Abstract] [Full Text] [Related]

  • 18. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials.
    Lin Y, Cai Z, Yuan J, Liu H, Pang X, Chen Q, Tang X, Geng Q, Dong S.
    Cardiovasc Diabetol; 2022 Nov 08; 21(1):237. PubMed ID: 36348348
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.